<document xmlns="http://cnx.rice.edu/cnxml">
  <title>Attention Deficit Disorders and Narcolepsy Disorder Drugs</title>
  <metadata xmlns:md="http://cnx.rice.edu/mdml">
    <md:title>Attention Deficit Disorders and Narcolepsy Disorder Drugs</md:title>
    <md:content-id>m00270</md:content-id>
    <md:uuid>75ac1813-9e7d-4117-894c-9a0200c12280</md:uuid>
  </metadata>
<content>
<section class="learning-objectives" id="sect-00001">
<title>Learning Outcomes</title>
<para id="para-00001">By the end of this section, you should be able to:</para>
<list id="list-00001">
<item>Identify the characteristics of drugs used to treat attention deficit disorders and narcolepsy.</item>
<item>Explain the indications, actions, adverse reactions, contraindications, and interactions of drugs used to treat attention deficit disorders and narcolepsy.</item>
<item>Describe nursing implications for drugs used in the treatment of attention deficit disorders and narcolepsy.</item>
<item>Explain the client education related to drugs used in the treatment of attention deficit disorders and narcolepsy.</item>
</list>
</section>
<para id="para-00002"><term class="no-emphasis" id="term-00001">Attention deficit hyperactivity disorder (ADHD)</term> is the most common psychiatric or neurobehavioral disorder in children. ADHD is more prevalent among males than females (NIMH, 2022). Various theories have been proposed regarding the actual etiology; however, no single theory has been accepted. This condition is characterized by persistent behavior demonstrating inattention, impulsivity, and/or hyperactivity that generally presents during childhood but can persist into adulthood (American Psychiatric Association, 2022). ADHD can be divided into three subcategories: predominantly inattentive type, predominantly hyperactive-impulsive type, or combined type (NIMH, 2022).</para>
<para id="para-00003">The goal of drug therapy is to control symptoms, facilitate learning, and promote social development. Commonly used agents are CNS stimulants, which are considered the first-line treatments for ADHD. These work by increasing the brain chemicals dopamine and norepinephrine, which play essential roles in thinking and attention. If a client is unable to tolerate the stimulant agents, nonstimulating drugs can be tried. Treatment includes a combination of medications, <term id="term-00002">cognitive behavioral therapy</term>, support groups and other therapies, stress management, and academic accommodations (NIMH, 2022).</para>
<para id="para-00004">Narcolepsy is a chronic neurological disorder characterized by excessive daytime sleepiness and sudden periods of sleep attacks at inopportune times. The cause is not completely understood but is possibly caused by several factors including autoimmune disorders, family history, or brain trauma (National Institute of Neurological Disorders and Stroke, n.d.). This condition affects males and females equally and usually begins during the teenage or young adult years. Most clients verbalize that the excess sleepiness substantially interferes with their daily lives, including work, school, home, and social life. <term id="term-00003">Cataplexy</term> is another common feature of narcolepsy. This condition is exhibited by loss of muscle function, ranging from slight weakness to complete body collapse. These episodes are frequently triggered by strong emotional reactions, such as laughing, anger, surprise, or fear, and last a duration of a few seconds to minutes. Cataplexy can occur several times per day to a few times a year. Other clinical manifestations of narcolepsy include <term id="term-00004">hypnagogic hallucinations</term> (sleep-related hallucinations that occur when falling asleep) and <term id="term-00005">sleep paralysis</term> (temporary inability to move when falling asleep or waking). Medications and lifestyle changes can manage the symptoms of narcolepsy (National Institute of Neurological Disorders and Stroke, n.d.).</para>
<section id="sect-00002">
<title/>
<section id="sect-00003">
<title>Central Nervous System Stimulants</title>
<para id="para-00005"><term class="no-emphasis" id="term-00006">CNS stimulants</term> are the mainstay of ADHD therapy. Although treating ADHD with a stimulant seems paradoxical, these drugs give the client the ability to maintain attention and focus on one activity for a longer period of time. These drugs redirect and excite the arousal stimuli from the RAS. They also help clients increase goal-oriented behavior. The impulsiveness and hyperactivity decline because the child is now able to concentrate on the task at hand. These drugs work by increasing the release of catecholamines from presynaptic neurons. In addition, amphetamines block the reuptake of NE and dopamine, which further increases their concentration so more of the drug can bind to the postsynaptic neuron. It is valuable to know that if one stimulant is ineffective, another should be tried before considering a nonstimulant.</para>
<para id="para-00006">The dosing schedule is important and is determined by the time course of the formulation selected. Most of these are available in immediate-release (IR), sustained release (SR), and 24-hour formulations. Most are controlled substances, and education should be provided to ensure these are not inappropriately used or distributed.</para>
<para id="para-00007">The following are the most common CNS stimulants:</para>
<list list-type="bulleted" id="list-00002">
<item><emphasis effect="italics">Methylphenidate (Class II controlled substance):</emphasis> This medication is a first-line treatment for ADHD and a second-line treatment for narcolepsy.</item>
<item><emphasis effect="italics">Amphetamine/dextroamphetamine (Class II controlled substance):</emphasis> This is a mixed-salt drug available in IR and ER formulations. The mechanism of action is to mediate CNS stimulation through the release of norepinephrine and dopamine. This is the only FDA-approved stimulant for use in children under age 3.</item>
<item><emphasis effect="italics">Dextroamphetamine:</emphasis> This drug releases NE from nerve terminals and increases the amounts of NE, dopamine, and serotonin.</item>
<item><emphasis effect="italics">Lisdexamfetamine:</emphasis> This is a <term id="term-00007">prodrug</term> of dextroamphetamine. It is used only in the treatment of ADHD and, recently, binge-eating disorders among adults. It is not approved for use in narcolepsy or as a weight-loss measure.</item>
<item><emphasis effect="italics">Methamphetamine:</emphasis> This is a highly addictive drug used to treat ADHD and narcolepsy. It is frequently used recreationally, and it is at high risk of being obtained and distributed for nontherapeutic uses.</item>
<item><emphasis effect="italics">Dexmethylphenidate:</emphasis> This drug is used to treat ADHD in clients age 6 and older. As with all stimulants, pediatric clients taking this medication should be monitored for evidence of hindered growth and development.</item>
<item><emphasis effect="italics">Modafinil (Class IV controlled substance):</emphasis> This drug improves wakefulness in clients with excessive daytime sleepiness associated with narcolepsy or shift-work sleep disorder and is used as an adjunctive therapy for obstructive sleep apnea/hypopnea syndrome. The drug can also be used to treat ADHD. Clients need to be aware that this drug can decrease the effectiveness of oral contraceptives.</item>
<item><emphasis effect="italics">Pitolisant:</emphasis> This is an H3 (histamine) blocker, not a controlled substance. It is used to treat excessive daytime sleepiness caused by narcolepsy and to treat cataplexy in adults with narcolepsy.</item>
</list>
<para id="para-00008">[link]Table 13.22[/link] lists common CNS stimulants and typical routes and dosing for adult and <term class="no-emphasis" id="term-00008">pediatric client</term>video.</para>
<table class="vertically-tight" id="table-00001">
<tgroup cols="2">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="2*"/>
<thead>
<row>
<entry valign="top" align="center"><emphasis effect="bold"><span class="blue-text">Drug</span></emphasis></entry>
<entry valign="top" align="center"><emphasis effect="bold"><span class="blue-text">Routes and Dosage Ranges</span></emphasis></entry>
</row>
</thead>
<tbody>
<row>
<entry valign="middle" align="center"><term class="no-emphasis" id="term-00009">Methylphenidate</term><newline/>
(<term class="no-emphasis" id="term-00010">Concerta, Ritalin, Daytrana</term>)</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue">ADHD</span></emphasis><newline/>
<emphasis effect="italics">Adults: Immediate release:</emphasis> Initial dose: 10–60 mg daily in 2–3 divided doses<newline/>
<emphasis effect="italics">Extended release:</emphasis> Initial dose: 20 mg in the morning; maximum dose: 60 mg/day.<newline/>
<emphasis effect="italics">Transdermal:</emphasis> Apply 10-mg patch to hip 2 hours before effect is needed. Remove 9 hours after application.<newline/>
<emphasis effect="italics">Children >6 years: Immediate release:</emphasis> 5 mg twice daily.<newline/>
<emphasis effect="bold">Narcolepsy</emphasis><newline/>
<emphasis effect="italics">Immediate release:</emphasis> Initial dose: 10 mg 2–3 times/day. Maximum dose: 60 mg/day.</entry>
</row>
<row>
<entry valign="middle" align="center"><term class="no-emphasis" id="term-00011">Amphetamine and dextroamphetamine</term><newline/>
(<term class="no-emphasis" id="term-00012">Adderall</term>)</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue">ADHD</span></emphasis><newline/>
<emphasis effect="italics">Adults: Immediate release:</emphasis> Initial dose: 5 mg 1–2 times/day. Maximum dose: 40 mg/day.<newline/>
<emphasis effect="italics">Extended release:</emphasis> Initial dose: 20 mg in the morning. Maximum dose: 60 mg/day.<newline/>
<emphasis effect="italics">Children 3</emphasis><emphasis effect="italics">–5 years:</emphasis> <emphasis effect="italics">Immediate-release:</emphasis> 2.5 mg/day; maximum dose: 30 mg/day.<newline/>
<emphasis effect="italics">Children ≥6 years: Immediate-release</emphasis>: 5 mg 1–2 times per day.<newline/>
<emphasis effect="italics">Extended-release:</emphasis> 5–10 mg/day; maximum dose: 30 mg/day.<newline/>
<emphasis effect="bold"><span class="blue">Narcolepsy</span></emphasis><newline/>
<emphasis effect="italics">Adults and children >12 years:</emphasis> <emphasis effect="italics">Immediate release:</emphasis> Initial dose: 10 mg/day; maximum dose: 60 mg/day.<newline/>
<emphasis effect="italics">Children 6</emphasis><emphasis effect="italics">–12 years:</emphasis> Initial dose: 5 mg/day.</entry>
</row>
<row>
<entry valign="middle" align="center"><term class="no-emphasis" id="term-00013">Dextroamphetamine</term><newline/>
(<term class="no-emphasis" id="term-00014">Xelstrym</term>)</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue">ADHD</span></emphasis><newline/>
<emphasis effect="italics">Adults:</emphasis> Initial dose: 9 mg/9 hours transdermally. Maximum dose: 18 mg/9 hours. Apply transdermally 2 hours before an effect is needed and remove within 9 hours.<newline/>
<emphasis effect="italics">Children (6 to 17 years):</emphasis> Initial dose: 4.5 mg/9 hours transdermally. Titrate dosage in weekly increments of 4.5 mg up to a maximum recommended dose of 18 mg/9 hours.</entry>
</row>
<row>
<entry valign="middle" align="center"><term class="no-emphasis" id="term-00015">Lisdexamfetamine</term><newline/>
(<term class="no-emphasis" id="term-00016">Vyvanse</term>)</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue">ADHD</span></emphasis><newline/>
<emphasis effect="italics">Adults and children ≥6 years:</emphasis> Initial dose: 30 mg/day in the morning; may increase by 10–20 mg at weekly intervals until optimal response is reached. Maximum dose: 70 mg/day.</entry>
</row>
<row>
<entry valign="middle" align="center"><term class="no-emphasis" id="term-00017">Methamphetamine</term><newline/>
(<term class="no-emphasis" id="term-00018">Desoxyn</term>)<newline/></entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue">ADHD</span></emphasis><newline/>
<emphasis effect="italics">Adults and children ≥6 years:</emphasis> Initial dose: 5 mg 1–2 times daily. Usual effective dose: 20–25 mg/day in 2 divided doses.</entry>
</row>
<row>
<entry valign="middle" align="center"><term class="no-emphasis" id="term-00019">Dexmethylphenidate</term><newline/>
(<term class="no-emphasis" id="term-00020">Focalin</term>)</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue">ADHD</span></emphasis><newline/>
<emphasis effect="italics">Adults and children ≥6 years:</emphasis> Initial dose: 2.5 mg orally twice daily, 4 hours apart; maximum dose: 10 mg twice daily.</entry>
</row>
<row>
<entry valign="middle" align="center"><term class="no-emphasis" id="term-00021">Serdexmethylphenidate and dexmethylphenidate</term><newline/>
(<term class="no-emphasis" id="term-00022">Azstarys</term>)</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue">ADHD</span></emphasis><newline/>
<emphasis effect="bold"><emphasis effect="italics">Adults and children 13–</emphasis></emphasis><emphasis effect="bold"><emphasis effect="italics">17 years:</emphasis></emphasis> Initial dose: 39.2 mg/7.8 mg/day in the morning; dosage may be increased after one week to 52.3 mg/10.4 mg/day.<newline/>
<emphasis effect="bold"><emphasis effect="italics">Children 6–</emphasis></emphasis><emphasis effect="bold"><emphasis effect="italics">12 years:</emphasis></emphasis> Initial dose: 39.2 mg/7.8 mg orally once daily in the morning; dosage may be increased to 52.3 mg/10.4 mg daily or decreased to 26.1 mg/5.2 mg daily after one week. Maximum dose: 52.3 mg/10.4 mg/day.</entry>
</row>
<row>
<entry valign="middle" align="center"><term class="no-emphasis" id="term-00023">Modafinil</term><newline/>
(<term class="no-emphasis" id="term-00024">Provigil</term>)</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue">ADHD</span></emphasis><newline/>
Initial dose: 100–300 mg/day.<newline/>
<emphasis effect="bold"><span class="blue">Narcolepsy and obstructive sleep apnea/hypopnea syndrome</span></emphasis><newline/>
Initial dose: 200 mg/day taken in the morning.<newline/>
<emphasis effect="bold"><span class="blue">Shift-work sleep disorder</span></emphasis><newline/>
Initial dose: 200 mg/day taken 1 hour prior to shift work.<newline/>
Dose must be reduced by 50% in clients with severe hepatic impairment.</entry>
</row>
<row>
<entry valign="middle" align="center"><term class="no-emphasis" id="term-00025">Pitolisant</term><newline/>
(<term class="no-emphasis" id="term-00026">Wakix</term>)<newline/></entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue">Narcolepsy</span></emphasis><newline/>
<emphasis effect="bold"><emphasis effect="italics">Adults and children ≥</emphasis></emphasis><emphasis effect="bold"><emphasis effect="italics">13 years:</emphasis></emphasis> <emphasis effect="bold">Administer once daily in the morning.</emphasis><newline/>
<emphasis effect="bold">Recommended dose: 17.8–</emphasis><emphasis effect="bold">35.6 mg/day orally.</emphasis><newline/>
<emphasis effect="bold">Week 1: Initiate with 8.9 mg/day orally.</emphasis><newline/>
<emphasis effect="bold">Week 2: Increase dose to 17.8 mg/day orally.</emphasis><newline/>
<emphasis effect="bold">Week 3: May increase to the maximum recommended dosage of 35.6 mg/day orally.</emphasis></entry>
</row>
</tbody>
</tgroup>
<caption><emphasis effect="bold">Drug Emphasis Table: CNS Stimulants</emphasis> (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
</table>
<note class="safety-alert" id="note-00001">
<title>Similarly Named Drugs Associated with CNS Stimulants</title>
<para id="para-00009">Do not confuse <term class="no-emphasis" id="term-00027">Adderall</term> (CNS stimulant) with <term class="no-emphasis" id="term-00028">Inderal</term> (<term class="no-emphasis" id="term-00029">beta blocker</term>).</para>
<para id="para-00010">(Source: ISMP, 2023)</para>
</note>
<section id="sect-00004">
<title>Adverse Effects and Contraindications</title>
<para id="para-00011">A client must use CNS stimulants with caution when pregnant and taking stimulants. Premature delivery and low birth weight have occurred in infants born to a parent taking these drugs.</para>
<para id="para-00012">Stimulants are contraindicated in glaucoma, hyperthyroidism, and the spectrum of cardiovascular diseases because they can exacerbate these conditions. Individuals with a history of drug or alcohol abuse/dependence should avoid these drugs because they have a high potential for physical and psychological dependence. Sudden cardiac arrest has occurred with the use of CNS stimulants. Studies have shown that the majority of these cases occurred in children with an undocumented cardiac defect. It is now recommended to obtain a baseline electrocardiogram (ECG, EKG) before beginning this therapy. To reduce the risk of insomnia, these medications should be taken in the morning or early afternoon. If a client has been diagnosed with a psychiatric disorder, they should avoid the CNS stimulants because they can worsen the preexisting psychiatric disorder. Motor and verbal tics can be intensified with the CNS stimulants, so it is essential to identify if there is a family history or personal diagnosis of Tourette syndrome.</para>
<para id="para-00013">The effects of phenytoin and tricyclic antidepressants (TCAs) are increased by the CNS stimulants. Also, lisdexamfetamine should not be used concurrently with TCAs or meperidine because it can potentiate the effects of these drugs, increasing the risk of adverse effects. MAOIs are contraindicated if currently taking or within 14 days of receiving the last dose, because both CNS stimulants and MAOIs can drastically increase blood pressure. The effects of alpha-1 adrenergic blockers can be reduced or negated by the CNS stimulants.</para>
<para id="para-00014">[link]Table 13.23[/link] is a drug prototype table for CNS stimulants featuring methylphenidate. It lists drug class, mechanism of action, adult and <term class="no-emphasis" id="term-00030">pediatric dosage</term>, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.</para>
<table class="vertically-tight" id="table-00002">
<tgroup cols="2">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="1*"/>
<tbody>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Class</span></emphasis><newline/>
CNS stimulant (Class II controlled substance)<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Mechanism of Action</span></emphasis><newline/>
Blocks the reuptake of norepinephrine and dopamine in specific areas of the brain</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Dosage</span></emphasis><newline/>
<emphasis effect="bold"><span class="blue-text">ADHD</span></emphasis><newline/>
<emphasis effect="italics">Adults: Immediate release:</emphasis> Initial dose: 10–60 mg daily in 2–3 divided doses.<newline/>
<emphasis effect="italics">Extended release:</emphasis> Initial dose: 20 mg in the morning; maximum dose: 60 mg/day.<newline/>
<emphasis effect="italics">Transdermal:</emphasis> Apply 10-mg patch to hip 2 hours before effect is needed. Remove 9 hours after application.<newline/>
<emphasis effect="italics">Children >6 years: Immediate release:</emphasis> 5 mg twice daily.<newline/>
<emphasis effect="bold"><span class="blue-text">Narcolepsy</span></emphasis><newline/>
<emphasis effect="italics">Immediate release:</emphasis> Initial dose: 10 mg 2–3 times/day. Maximum dose: 60 mg/day.</entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Indications</span></emphasis><newline/>
ADHD<newline/>
Narcolepsy<newline/>
Traumatic brain injury (TBI)<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Therapeutic Effects</span></emphasis><newline/>
Enhances dopamine and NE actions in certain brain regions to improve attention, concentration, and wakefulness<newline/>
Enhancement of dopamine in the basal ganglia may improve hyperactivity.</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Interactions</span></emphasis><newline/>
Concomitant use of MAOIs or within 14 days of MAOI use<newline/>
Alpha-1 adrenergic blockers<newline/>
Phenytoin<newline/>
Tricyclic antidepressants<newline/>
Meperidine<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Food Interactions</span></emphasis><newline/>
Alcohol<newline/>
Caffeine</entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Adverse Effects</span></emphasis><newline/>
Insomnia<newline/>
Headaches/seizures<newline/>
Heart palpitations/tachyarrhythmias<newline/>
Angina<newline/>
Sudden cardiac death<newline/>
CVA<newline/>
Hypertension<newline/>
Leukopenia and anemia<newline/>
Hyperhidrosis<newline/>
Irritability/nervousness<newline/>
Anorexia/weight loss<newline/>
Potential for dependence and abuse<newline/>
Suppression of growth in children with long-term use<newline/>
Exacerbation of preexisting or emergence of new psychiatric disorders such as psychosis or mania<newline/>
Contact dermatitis with transdermal application</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Contraindications</span></emphasis><newline/>
Advanced arteriosclerosis<newline/>
Symptomatic cardiovascular disease<newline/>
Congenital cardiac structural abnormalities<newline/>
Recent MI or angina<newline/>
Severe hypertension<newline/>
Heart failure<newline/>
Arrhythmias<newline/>
Hyperthyroidism<newline/>
Glaucoma<newline/>
History of substance use<newline/>
History of psychiatric disorders<newline/>
Family history or personal diagnosis of Tourette syndrome<newline count="2"/>
Caution:<newline/>
Pregnancy/breastfeeding<newline/>
Seizures</entry>
</row>
</tbody>
</tgroup>
<caption><emphasis effect="bold">Drug Prototype Table: Methylphenidate</emphasis> (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
</table>
</section>
</section>
<section id="sect-00005">
<title>CNS Nonstimulants</title>
<para id="para-00015">These alternative drugs for ADHD and narcolepsy are not associated with the many cardiac and systemic stimulatory effects experienced with the CNS stimulants. They are preferable in clients who are unable to tolerate the stimulatory effects of the other drugs. The following are the most common <term class="no-emphasis" id="term-00031">CNS nonstimulants</term>:</para>
<list list-type="bulleted" id="list-00003">
<item><emphasis effect="italics">Atomoxetine:</emphasis> This is an SNRI with anticholinergic effects used to treat ADHD. It inhibits reuptake of NE in nerve synapses. It has little risk for abuse and dependence; therefore, it is not a controlled substance.</item>
<item><emphasis effect="italics">Guanfacine:</emphasis> This is a selective alpha-2 adrenergic agonist. It is not a controlled substance. Guanfacine does not produce CNS stimulation but instead can cause significant CNS depression. As an alpha-2 agonist, sympathetic nerve impulses are reduced. Furthermore, it binds specifically to postsynaptic alpha-2A adrenoreceptors in the prefrontal cortex. As a result, working memory and behavioral inhibitions are affected, which improves symptoms associated with ADHD.</item>
<item><emphasis effect="italics">Clonidine:</emphasis> This is an alpha-2 adrenergic agonist. The mechanism of action in ADHD is unknown.</item>
<item><emphasis effect="italics">Viloxazine:</emphasis> This drug is a selective NE reuptake inhibitor for the treatment of ADHD in adults and pediatric clients age 6 and older.</item>
<item><emphasis effect="italics">Solriamfetol:</emphasis> This drug is a dopamine and norepinephrine reuptake inhibitor (DNRI) that improves daytime wakefulness in adult clients with narcolepsy or obstructive sleep apnea (OSA).</item>
<item><emphasis effect="italics">Sodium oxybate (Class III controlled substance):</emphasis> This is the first once-at-bedtime medication for people with narcolepsy. The extended-release formulation treats cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. It has not been tested in children or pregnant individuals; therefore, it must be avoided in these populations. This CNS depressant drug is the sodium salt of gamma-hydroxybutyrate (GHB). Abuse or misuse of illicit GHB is associated with CNS adverse reactions, including seizure, respiratory depression, decreased consciousness, coma, and death. It is available only through a restricted program called the Lumryz REMS. It is contraindicated in combination with sedative-hypnotics or alcohol. Adverse effects include depression and suicidality, confusion/anxiety, and <term id="term-00032">parasomnias</term>. Ingesting high sodium content while taking this drug can exacerbate heart failure or hypertension, or further impair renal function.</item>
</list>
<para id="para-00016">[link]Table 13.24[/link] lists common CNS nonstimulants and typical routes and dosing for adult and <term class="no-emphasis" id="term-00033">pediatric clients</term>.</para>
<table class="vertically-tight" id="table-00003">
<tgroup cols="2">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="2*"/>
<thead>
<row>
<entry valign="top" align="center"><emphasis effect="bold"><span class="blue-text">Drug</span></emphasis></entry>
<entry valign="top" align="center"><emphasis effect="bold"><span class="blue-text">Routes and Dosage Ranges</span></emphasis></entry>
</row>
</thead>
<tbody>
<row>
<entry valign="middle" align="center"><term class="no-emphasis" id="term-00034">Atomoxetine</term><newline/>
(<term class="no-emphasis" id="term-00035">Strattera</term>)</entry>
<entry valign="top" align="left"><emphasis effect="italics">Adults and children >70 kg:</emphasis> 40 mg/day orally. Gradually increase to a target daily dose of 80 mg. Maximum dose: 100 mg/day.<newline/>
<emphasis effect="italics">Children ≤70 kg:</emphasis> Initial dose: 0.5 mg/kg/day; target dose: 1.2 mg/kg/day; maximum dose: 1.4 mg/kg/day.</entry>
</row>
<row>
<entry valign="middle" align="center"><term class="no-emphasis" id="term-00036">Guanfacine</term><newline/>
(<term class="no-emphasis" id="term-00037">Intuniv</term>)</entry>
<entry valign="top" align="left"><emphasis effect="italics">Adults and children ≥6 years:</emphasis> <emphasis effect="italics">Extended-release tablet:</emphasis> Initial dose: 1 mg/day; maximum dose: 4 mg/day.</entry>
</row>
<row>
<entry valign="middle" align="center"><term class="no-emphasis" id="term-00038">Clonidine</term><newline/>
(<term class="no-emphasis" id="term-00039">Kapvay</term>)</entry>
<entry valign="top" align="left"><emphasis effect="italics">Adults and children >6 years:</emphasis> Initial dose: 0.1 mg/day tablet at bedtime for 1 week. Increase daily dosage in increments of 0.1 mg/day each week until desired response is achieved.</entry>
</row>
<row>
<entry valign="middle" align="center"><term class="no-emphasis" id="term-00040">Viloxazine</term><newline/>
(<term class="no-emphasis" id="term-00041">Qelbree</term>)<newline/></entry>
<entry valign="top" align="left"><emphasis effect="italics">Adults:</emphasis> Initial dose: 200 mg/day orally; increase dose as needed and tolerated; maximum dose: 600 mg/day.<newline/>
<emphasis effect="italics">Children 12–17 years:</emphasis> Initial dose: 200 mg/day orally; increase dose as needed and tolerated; maximum dose: 400 mg/day.<newline/>
<emphasis effect="italics">Children 6–11 years:</emphasis> Initial dose: 100 mg/day orally; increase dose as needed and tolerated; maximum dose: 400 mg/day.<newline/>
<emphasis effect="italics">Children &lt;6 years:</emphasis> Use and dose must be determined by the provider.</entry>
</row>
<row>
<entry valign="middle" align="center"><term class="no-emphasis" id="term-00042">Solriamfetol</term><newline/>
(<term class="no-emphasis" id="term-00043">Sunosi</term>)</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Narcolepsy</span></emphasis><newline/>
Initial dose: 75 mg/day orally; maximum dose: 150 mg/day orally.<newline/>
<emphasis effect="bold"><span class="blue-text">Sleep apnea</span></emphasis><newline/>
Initial dose: 37.5 mg/day orally; maximum dose: 150 mg/day orally.<newline/>
<emphasis effect="italics">Adults:</emphasis> Administer once daily upon awakening. Avoid administration within 9 hours of planned bedtime due to potential to interfere with sleep.<newline/>
<emphasis effect="italics">Children:</emphasis> Safety and effectiveness have not yet been established.</entry>
</row>
<row>
<entry valign="middle" align="center"><term class="no-emphasis" id="term-00044">Sodium oxylate</term><newline/>
(<term class="no-emphasis" id="term-00045">Lumryz</term>)</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Narcolepsy</span></emphasis><newline/>
Initial dose: 4.5 g orally once nightly; titrate in increments of 1.5 g per night at weekly intervals. Recommended dose: 6–9 g once per night orally.</entry>
</row>
</tbody>
</tgroup>
<caption><emphasis effect="bold">Drug Emphasis Table: CNS Nonstimulants</emphasis> (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
</table>
<section id="sect-00006">
<title>Adverse Effects and Contraindications</title>
<para id="para-00017">Adverse effects seen with atomoxetine are mainly related to its anticholinergic effects. These include dry mouth, blurred vision, nausea, constipation, and urine retention. Guanfacine and clonidine can cause sedation, severe hypotension, and bradycardia. Antihypertensives and CNS depressants are contraindicated with these due to the additive effects they can have on blood pressure and sedation. Taking guanfacine with a high-fat meal can cause increased absorption of the drug.</para>
<para id="para-00018">TCAs can increase blood pressure and may counteract clonidine’s hypotensive effects. Monitor blood pressure and adjust as needed. Antihypertensive agents will potentiate the hypotensive effects of clonidine. CNS depressants can potentiate sedating effects. It is recommended to avoid concomitant use. Digoxin, calcium channel blockers, and beta blockers should not be used in conjunction with clonidine because they can exacerbate bradycardia and AV block.</para>
<note class="safety-alert" id="note-00002">
<title>Similarly Named Drugs Associated with CNS Nonstimulants</title>
<para id="para-00019">Do not confuse <term class="no-emphasis" id="term-00046">Intuniv</term> (CNS nonstimulant) with <term class="no-emphasis" id="term-00047">Invega</term> (<term class="no-emphasis" id="term-00048">antipsychotic</term>).</para>
<para id="para-00020">(Source: ISMP, 2023)</para>
</note>
<para id="para-00021">[link]Table 13.25[/link] is a drug prototype table for CNS nonstimulants featuring clonidine. It lists drug class, mechanism of action, adult and <term class="no-emphasis" id="term-00049">pediatric dosage</term>, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.</para>
<table class="vertically-tight" id="table-00004">
<tgroup cols="2">
<colspec colnum="1" colname="c1" colwidth="1*"/>
<colspec colnum="2" colname="c2" colwidth="1*"/>
<tbody>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Class</span></emphasis><newline/>
CNS nonstimulant, alpha-2 adrenergic agonist<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Mechanism of Action</span></emphasis><newline/>
Unknown</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Dosage</span></emphasis><newline/>
<emphasis effect="italics">Adults and children >6 years:</emphasis> Initial dose: 0.1 mg/day tablet at bedtime for 1 week. Increase daily dosage in increments of 0.1 mg/day each week until desired response is achieved.</entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Indications</span></emphasis><newline/>
ADHD as a monotherapy or as an adjunct to a CNS stimulant<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Therapeutic Effects</span></emphasis><newline/>
Reduces sympathetic outflow from the CNS</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Drug Interactions</span></emphasis><newline/>
Tricyclic antidepressants<newline/>
Antihypertensive agents<newline/>
CNS depressants<newline/>
Drugs that affect sinus node function or AV node conduction (digoxin, calcium channel blockers, and beta blockers)<newline count="2"/>
<emphasis effect="bold"><span class="blue-text">Food Interactions</span></emphasis><newline/>
No significant interactions</entry>
</row>
<row>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Adverse Effects</span></emphasis><newline/>
Hypotension<newline/>
Bradycardia/syncope<newline/>
Sedation<newline/>
Rebound hypertension with abrupt withdrawal<newline/>
Allergic reactions (generalized rash, angioedema)</entry>
<entry valign="top" align="left"><emphasis effect="bold"><span class="blue-text">Contraindications</span></emphasis><newline/>
Hypersensitivity to any of the ingredients<newline count="2"/>
Caution:<newline/>
Heart block<newline/>
Cardiovascular disease<newline/>
Cerebrovascular disease<newline/>
Chronic renal failure</entry>
</row>
</tbody>
</tgroup>
<caption><emphasis effect="bold">Drug Prototype Table: Clonidine</emphasis> (source: https://dailymed.nlm.nih.gov/dailymed/)</caption>
</table>
</section>
</section>
<section id="sect-00007">
<title>Nursing Implications</title>
<para id="para-00022">The nurse should do the following for clients who are taking CNS stimulants and nonstimulants:</para>
<list list-type="bulleted" id="list-00004">
<item>Screen and monitor client’s cardiovascular risk factors, such as family history, smoking, elevated lipids, hypertension, diabetes mellitus, and obesity.</item>
<item>Assess client’s psychiatric history.</item>
<item>Measure and document blood pressure readings, heart rate, weight, food intake, and amount of uninterrupted sleep.</item>
<item>Obtain a baseline ECG prior to beginning therapy and during episodes of chest pain or palpitations.</item>
<item>Provide drug holidays to children for the purpose of determining the need for continued treatment and allow for “catch-up” growth.</item>
<item>Monitor for improved attention span and task performance in both children and adults.</item>
<item>Observe for a decrease in hyperactivity in children along with functioning appropriately during social interactions with other children.</item>
<item>Assess for fewer sleep episodes during normal waking hours.</item>
<item>Ensure nutritional needs are being met.</item>
<item>Provide client teaching regarding the drug and when to call the health care provider. See below for client teaching guidelines.</item>
</list>
<note class="client-teaching" id="note-00003">
<para id="para-00023"><emphasis effect="bold">The client taking a CNS stimulant or nonstimulant should:</emphasis></para>
<list list-type="bulleted" id="list-00005">
<item>Report chest pain, difficulty breathing, fainting, abnormal thinking or behavior, increased aggression, hallucinations, and unintended weight loss.</item>
<item>Take immediate-release tablets, chewable tablets, and solution 30–45 minutes before meals.</item>
<item>Drink at least 8 oz. of water with chewable tablets to avoid choking.</item>
<item>Weigh self at least once a week.</item>
<item>Be cognizant of caloric and nutrient intake to avoid excessive weight loss.</item>
<item>Eat prior to taking the medication to minimize appetite suppression.</item>
</list>
<para id="para-00024"><emphasis effect="bold">The client taking a CNS stimulant or nonstimulant<emphasis effect="italics">should not:</emphasis></emphasis></para>
<list list-type="bulleted" id="list-00006">
<item>Chew or crush sustained- or extended-release formulations.</item>
<item>Take a CNS stimulant after 6 pm or less than 6 hours before bedtime.</item>
<item>Take less than 1 tablet per day.</item>
<item>Take guanfacine with a high-fat meal.</item>
<item>Take more than prescribed or distribute to others.</item>
<item>Drive or participate in any activities that require alertness until the effects of nonstimulants are known.</item>
</list>
</note>
<note class="black-box" id="note-00004">
<para id="para-00025"><emphasis effect="bold">CNS Stimulants and Nonstimulants</emphasis></para>
<para id="para-00026"><emphasis effect="bold">Atomoxetine, viloxazine:</emphasis> In clinical studies, higher rates of suicidal thoughts and behavior were reported in clients with ADHD treated with atomoxetine or viloxazine than in clients treated with placebo.</para>
<para id="para-00027"><emphasis effect="bold">Dextroamphetamine, lisdexamfetamine</emphasis>, and <emphasis effect="bold">dexmethylphenidate</emphasis> have a high abuse potential.</para>
<para id="para-00028"><emphasis effect="bold">Sodium oxybate</emphasis> has a risk of causing clinically significant respiratory depression. This medication also has a high risk of abuse or misuse.</para>
</note>
</section>
</section>
<section class="chapter-summary" id="sect-00008">
<para id="para-00029">This chapter discussed various common mental health disorders and the drug classifications used in managing them. Some of these classifications can be used in more than one disorder. Likewise, multiple drug classifications can be used in treating a single mental health condition. Several of these classifications are associated with maintaining a balance of the neurotransmitters involved. For instance, antidepressants such as SSRIs, SNRIs, and NDRIs increase neurotransmitters’ availability to receptors for longer periods of time. Mood stabilizers, such as lithium, are beneficial in preventing or reducing fluctuations in mood. Antipsychotics are useful in treating the symptoms of schizophrenia. Overall, these drugs can enhance the ability of clients to have the opportunity to live an independent life and be a positive contributor to society. As further research expands our knowledge base, it will continue to alter the treatment of mental health disorders. Furthermore, as the new growth of information is shared, it can play a major role in diminishing the stigma long associated with mental-health illness.</para>
</section>
<section class="review-questions" id="sect-00009">
<title>Review Questions</title>
<exercise id="exer-00001"><problem id="prob-00001"><para id="para-00030"><link class="os-embed" url="#exercise/PHAR_Ch13_Sec01_RQ1"/></para></problem></exercise>
<exercise id="exer-00002"><problem id="prob-00002"><para id="para-00031"><link class="os-embed" url="#exercise/PHAR_Ch13_Sec03_RQ2"/></para></problem></exercise>
<exercise id="exer-00003"><problem id="prob-00003"><para id="para-00032"><link class="os-embed" url="#exercise/PHAR_Ch13_Sec05_RQ3"/></para></problem></exercise>
<exercise id="exer-00004"><problem id="prob-00004"><para id="para-00033"><link class="os-embed" url="#exercise/PHAR_Ch13_Sec01_RQ4"/></para></problem></exercise>
<exercise id="exer-00005"><problem id="prob-00005"><para id="para-00034"><link class="os-embed" url="#exercise/PHAR_Ch13_Sec02_RQ5"/></para></problem></exercise>
<exercise id="exer-00006"><problem id="prob-00006"><para id="para-00035"><link class="os-embed" url="#exercise/PHAR_Ch13_Sec01_RQ6"/></para></problem></exercise>
<exercise id="exer-00007"><problem id="prob-00007"><para id="para-00036"><link class="os-embed" url="#exercise/PHAR_Ch13_Sec02_RQ7"/></para></problem></exercise>
<exercise id="exer-00008"><problem id="prob-00008"><para id="para-00037"><link class="os-embed" url="#exercise/PHAR_Ch13_Sec01_RQ8"/></para></problem></exercise>
<exercise id="exer-00009"><problem id="prob-00009"><para id="para-00038"><link class="os-embed" url="#exercise/PHAR_Ch13_Sec04_RQ9"/></para></problem></exercise>
<exercise id="exer-00010"><problem id="prob-00010"><para id="para-00039"><link class="os-embed" url="#exercise/PHAR_Ch13_Sec05_RQ10"/></para></problem></exercise>
</section>
<section class="references" id="sect-00010">
<para id="para-00040">Ameer, M., &amp; Saadabadi, A. (2023). <emphasis effect="italics">Neuroleptic medications.</emphasis> StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK459150/</para>
<para id="para-00041">American Geriatrics Society. (2023). American Geriatrics Society 2023 updated AGS Beers criteria® for potentially inappropriate medication use in older adults. <emphasis effect="italics">Journal of American Geriatrics Society, 71,</emphasis> 1–30. https://doi.org/10.1111/jgs.18372</para>
<para id="para-00042">American Psychiatric Association. (2022). <emphasis effect="italics">Diagnostic and statistical manual of mental disorders</emphasis> (5th ed., text rev.). (DSM-5-TR). American Psychiatric Association.</para>
<para id="para-00043">Correll, C., &amp; Schooler, N. (2020). Negative symptoms in schizophrenia: A review and clinical guide for recognition, assessment, and treatment. <emphasis effect="italics">Neuropsychiatric Disease and Treatment</emphasis>, <emphasis effect="italics">16</emphasis>, 519–534. https://doi.org/10.2147/NDT.S225643</para>
<para id="para-00044">Chu, A., &amp; Wadhwa, R. (2023). <emphasis effect="italics">Selective serotonin reuptake inhibitors.</emphasis> StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK554406/</para>
<para id="para-00045">Coryell, W. (2022). Drug treatment of bipolar disorders. <emphasis effect="italics">Merck Manual Professional Version.</emphasis> https://www.merckmanuals.com/professional/psychiatric-disorders/mood-disorders/drug-treatment-of-bipolar-disorders</para>
<para id="para-00046">DailyMed. (Updated May 30, 2023). <emphasis effect="italics">Adderall – dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f22635fe-821d-4cde-aa12-419f8b53db81</para>
<para id="para-00047">DailyMed. (Updated October 24, 2022). <emphasis effect="italics">Adderall XR – dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine sulfate and amphetamine aspartate capsule, extended release</emphasis>. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aff45863-ffe1-4d4f-8acf-c7081512a6c0</para>
<para id="para-00048">DailyMed. (Updated January 10, 2023). <emphasis effect="italics">Alprazolam, tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a23063c0-099a-4256-b95f-3a857bbf704b</para>
<para id="para-00049">DailyMed. (Updated March 22, 2023). <emphasis effect="italics">Amitriptyline hydrochloride, film coated.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f780d3c0-1247-5ad2-e053-6394a90a4454</para>
<para id="para-00050">DailyMed. (Updated May 17, 2023). <emphasis effect="italics">Aripiprazole, tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d8d574b-fbf4-4d2c-a37c-25556ecbf1aa</para>
<para id="para-00051">DailyMed. (Updated May 10, 2023). <emphasis effect="italics">Atomoxetine capsule.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f6bea0c-297b-43ff-8960-ecc11243e06e</para>
<para id="para-00052">DailyMed. (Updated November 3, 2022). <emphasis effect="italics">Azstarys – serdexmethylphenidate and dexmethylphenidate capsule.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00b5e716-5564-4bbd-acaf-df2bc45a5663</para>
<para id="para-00053">DailyMed. (Updated February 28, 2023). <emphasis effect="italics">Belsomra – suvorexant tablet, film coated.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e5b72731-1acb-45b7-9c13-290ad12d3951</para>
<para id="para-00054">DailyMed. (Updated March 30, 2023). <emphasis effect="italics">Bupropion HCL tablet, film coated</emphasis>. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f820ad7d-3c88-4a4f-e053-6294a90aef7b</para>
<para id="para-00055">DailyMed. (Updated June 15, 2023). <emphasis effect="italics">Carbamazepine tablet, extended release.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=282c954f-e34a-4bd5-b5eb-771e3c56936f</para>
<para id="para-00056">DailyMed. (Updated August 24, 2023). <emphasis effect="italics">Chlorpromazine hydrochloride, film coated.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa086a21-de85-4b03-af58-49b70acf8cf0</para>
<para id="para-00057">DailyMed. (Updated February 9, 2022). <emphasis effect="italics">Citalopram capsule.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f815b0c-6da7-cb61-e89c-7de628092d0d</para>
<para id="para-00058">DailyMed. (Updated February 2, 2023). <emphasis effect="italics">Clonazepam tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1582eb7-af35-45d5-a52e-0e380d08527d</para>
<para id="para-00059">DailyMed. (Updated February 15, 2023). <emphasis effect="italics">Clozapine tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=883b5d43-0339-7dc1-f775-93791fb9b978DailyMed. (Updated May 25, 2023).</para>
<para id="para-00060">DailyMed. (Updated May 25, 2023). <emphasis effect="italics">Dayvigo-lemborexant tablet, film coated.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7074cb65-77b3-45d2-8e8d-da8dc0f70bfd</para>
<para id="para-00061">DailyMed. (Updated November 16, 2022). <emphasis effect="italics">Desipramine HCL tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ed9d2290-9ad9-ecff-e053-2a95a90a5fd6</para>
<para id="para-00062">DailyMed. (Updated December 10, 2021). <emphasis effect="italics">Dexmethylphenidate hydrochloride capsule, extended-release.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b7e5069-6c58-4093-bb19-37d52fe67fd6</para>
<para id="para-00063">DailyMed. (Updated August 19, 2022). <emphasis effect="italics">Dexmethylphenidate hydrochloride tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=830df993-db01-40df-beef-90af6b86f561</para>
<para id="para-00064">DailyMed. (Updated April 7, 2023). <emphasis effect="italics">Diazepam injection.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f466f8a3-f31c-44f4-b0e8-444464f20f66</para>
<para id="para-00065">DailyMed. (Updated July 6, 2023). <emphasis effect="italics">Diazepam tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75661b9e-576a-4bde-aecd-587fdfdf1c28</para>
<para id="para-00066">DailyMed. (Updated July 20, 2023). <emphasis effect="italics">Doxepin HCL capsule.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eb643108-7ae2-f476-e053-2995a90ab148</para>
<para id="para-00067">DailyMed. (Updated August 7, 2023). <emphasis effect="italics">Duloxetine hydrochloride capsule, delayed release.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=177ce798-3924-416b-ba37-23dfa911a43b</para>
<para id="para-00068">DailyMed. (Updated March 28, 2022). <emphasis effect="italics">Escitalopram oxalate tablet, film-coated.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8704d062-fa91-4224-9dec-41664d20ee6b</para>
<para id="para-00069">DailyMed. (Updated October 24, 2022). <emphasis effect="italics">Eszopiclone tablet, film-coated.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5469cc59-78f9-447a-9c33-12553bb4073d</para>
<para id="para-00070">DailyMed. (Updated June 16, 2021). <emphasis effect="italics">Fluoxetine HCL tablet, film-coated.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b47b291f-3340-0c2a-3585-0926b9c1a71f</para>
<para id="para-00071">DailyMed. (Updated August 19, 2023). <emphasis effect="italics">Fluphenazine hydrochloride tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e73764e7-e666-4ad3-a029-04a528dc1c9e</para>
<para id="para-00072">DailyMed. (Updated November 11, 2022). <emphasis effect="italics">Guanfacine tablet extended-release.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1c492e87-3406-ddb8-aaf2-e609c2ded503</para>
<para id="para-00073">DailyMed. (Updated July 24, 2023). <emphasis effect="italics">Haloperidol decanoate injection.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f2d14406-2ad4-4c5b-9c24-a026f27b415d</para>
<para id="para-00074">DailyMed (Updated January 29, 2021). <emphasis effect="italics">Haloperidol lactate injection</emphasis>. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8397a841-f240-4767-9dcd-781e6d3f7c7f</para>
<para id="para-00075">DailyMed. (Updated November 11, 2022). <emphasis effect="italics">Haloperidol, tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a474e06-fb00-40cb-aa3a-6edad43c2c0a</para>
<para id="para-00076">DailyMed. (Updated November 2, 2022). <emphasis effect="italics">Kapvay – Clonidine hydrochloride tablet, extended release.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa7700e2-ae5d-44c4-a609-76de19c705a7</para>
<para id="para-00077">DailyMed. (Updated October 18, 2022). <emphasis effect="italics">Lamotrigine tablet, extended release.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ecb7a528-699f-4e51-9887-dee60456da2f</para>
<para id="para-00078">DailyMed. (Updated July 12, 2023). <emphasis effect="italics">Levomilnacipran capsule, extended release.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bcbc5d92-e022-4a0d-ab4d-2b0d7aa68c58</para>
<para id="para-00079">DailyMed. (Updated January 27, 2023). <emphasis effect="italics">Lithium carbonate capsule.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d1800f34-3d67-4b2f-874e-8639b125d853</para>
<para id="para-00080">DailyMed. (Updated September 12, 2022). <emphasis effect="italics">Lorazepam injection.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5b17cde-a94c-4105-871c-54e7d2bd47e8</para>
<para id="para-00081">DailyMed. (Updated December 20, 2022). <emphasis effect="italics">Lorazepam tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4fae1607-69d7-47ce-9b78-7474af50036d</para>
<para id="para-00082">DailyMed. (Updated June 7, 2023). <emphasis effect="italics">Lumryz – sodium oxybate for suspension, extended release</emphasis>. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10e5e40c-52f3-4c73-8a34-2c29c690a934</para>
<para id="para-00083">DailyMed. (Updated March 23, 2023). <emphasis effect="italics">Lurasidone hydrochloride tablet, coated.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f5f8228-1304-4981-8577-029136627260</para>
<para id="para-00084">DailyMed. (Updated July 17, 2023). <emphasis effect="italics">Marplan – isocarboxazid tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac387aa0-3f04-4865-a913-db6ed6f4fdc5</para>
<para id="para-00085">DailyMed. (Updated July 5, 2023). <emphasis effect="italics">Methamphetamine hydrochloride tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f31f580f-1f08-4a0f-b078-0b9e3308f712</para>
<para id="para-00086">DailyMed. (Updated June 16, 2021). <emphasis effect="italics">Methylphenidate capsule, extended-release.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f8983ce-71b8-4c62-830d-e4692ddededa</para>
<para id="para-00087">DailyMed. (Updated May 3, 2023). <emphasis effect="italics">Methylphenidate hydrochloride tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4f3c91e6-4576-4326-bdab-7d8fb7c09bb8</para>
<para id="para-00088">DailyMed. (Updated June 5, 2023). <emphasis effect="italics">Methylphenidate transdermal system – methylphenidate patch.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bcff873-1fc2-45bc-a8e4-5db4edeb9bfb</para>
<para id="para-00089">DailyMed. (Updated December 1, 2022). <emphasis effect="italics">Midazolam hydrochloride injection, solution</emphasis>. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b42059c-16ad-4826-829b-83b42a39435b</para>
<para id="para-00090">DailyMed. (Updated November 30, 2022). <emphasis effect="italics">Midazolam hydrochloride syrup.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a833c24b-6dca-44d7-a0d6-20012fa1ea77</para>
<para id="para-00091">DailyMed. (Updated May 2, 2023). <emphasis effect="italics">Mirtazapine tablet, film coated.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9675333e-3064-c8cb-a4b4-6c74d9a82f17</para>
<para id="para-00092">DailyMed. (Updated February 24, 2022). <emphasis effect="italics">Modafinil tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=63604fef-0b80-40ce-8dbf-3384f1aee395</para>
<para id="para-00093">DailyMed. (Updated December 9, 2020). <emphasis effect="italics">Nardil – phenelzine sulfate tablet, film coated.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=513a41d0-37d4-4355-8a6d-a2c643bce6fa</para>
<para id="para-00094">DailyMed. (Updated November 8, 2022). <emphasis effect="italics">Olanzapine tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=636665be-9d7e-443a-8134-e8cc47e6ba24</para>
<para id="para-00095">DailyMed. (Updated November 11, 2022). <emphasis effect="italics">Paliperidone tablet, extended release.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b269778-803b-4ce2-a8c0-636fb131d16a</para>
<para id="para-00096">DailyMed. (Updated December 6, 2022). <emphasis effect="italics">Paroxetine hydrochloride tablet, film coated, extended release.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=087ff0d3-1761-47ea-a8c1-7c4cb679af97</para>
<para id="para-00097">DailyMed. (Updated October 10, 2022). <emphasis effect="italics">Qelbree – Viloxazine hydrochloride capsule, extended release.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aedf408d-0f84-418d-9416-7c39ddb0d29a</para>
<para id="para-00098">DailyMed. (Updated February 21, 2022). <emphasis effect="italics">Quetiapine fumarate, quetiapine tablet, film coated, extended release.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6562eb60-0d70-4909-bd07-88d5c9241516</para>
<para id="para-00099">DailyMed. (Updated May 16, 2023). <emphasis effect="italics">Quviviq – daridorexant tablet, film coated.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a2d1503-b816-40c9-9fac-7e03c5a3bcef</para>
<para id="para-00100">DailyMed. (Updated January 12, 2022). <emphasis effect="italics">Ramelteon tablet, film coated.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d0cc378-4bc5-425c-8f41-43eb734c24d9</para>
<para id="para-00101">DailyMed. (Updated July 18, 2022). <emphasis effect="italics">Risperidone tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=43aa2a4f-1123-4f86-800b-9218882f7bcd</para>
<para id="para-00102">DailyMed. (Updated March 3, 2023). <emphasis effect="italics">Selegiline hydrochloride capsule.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df88d6bf-0fda-3825-e053-2a95a90a3a75</para>
<para id="para-00103">DailyMed. (Updated July 21, 2017). <emphasis effect="italics">Sertraline hydrochloride tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa1026ed-fcaa-4442-a3f8-b5e0b600b51f</para>
<para id="para-00104">DailyMed. (Updated October 20, 2021). <emphasis effect="italics">Sunosi – solriamfetol tablet, film coated.</emphasis>https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f30ab12-20e1-4391-9359-24b23a21578d</para>
<para id="para-00105">DailyMed. (Updated February 28, 2023). <emphasis effect="italics">Temazepam capsule.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4370eb4-b00d-4247-af8d-980e59fbbec6</para>
<para id="para-00106">DailyMed. (Updated December 16, 2021). <emphasis effect="italics">Thioridazine hydrochloride tablet, film coated.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=52fea941-0b47-41c1-b00d-f88150e8ab93</para>
<para id="para-00107">DailyMed. (Updated April 3, 2023). <emphasis effect="italics">Trintellix – vortioxetine tablet, film coated.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb1e9df4-dd74-4073-9d78-bb55593dd000</para>
<para id="para-00108">DailyMed. (Updated March 31, 2023). <emphasis effect="italics">Trazodone HCL tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d27e4473-6f62-ddfe-e053-2a95a90a9a2c</para>
<para id="para-00109">DailyMed. (Updated January 16, 2023). <emphasis effect="italics">Triazolam tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db564864-17fc-4ba5-a438-a467ef57a0ca</para>
<para id="para-00110">DailyMed. (Updated March 30, 2023). <emphasis effect="italics">Valproic acid capsule.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d4df6ad-3d53-4664-9200-749487bf3689</para>
<para id="para-00111">DailyMed. (Updated May 19, 2023). <emphasis effect="italics">Venlafaxine hydrochloride capsule, extended release.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=85d3ce8b-8966-45d9-bdaf-f6f0475096e1</para>
<para id="para-00112">DailyMed. (Updated November 11, 2022). <emphasis effect="italics">Vraylar – cariprazine capsule, gelatin coated</emphasis>. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3435ec73-86ed-46d1-bd1f-ee6c30209123</para>
<para id="para-00113">DailyMed. (Updated July 12, 2023). <emphasis effect="italics">Vyvanse – lisdexamfetamine dimesylate, capsule and chewable.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=704e4378-ca83-445c-8b45-3cfa51c1ecad</para>
<para id="para-00114">DailyMed. (Updated December 22, 2022). <emphasis effect="italics">Wakix – pitolisant hydrochloride tablet, film coated</emphasis>. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8daa5562-824e-476c-9652-26ceef3d4b0e</para>
<para id="para-00115">DailyMed. (Updated August 21, 2023). <emphasis effect="italics">Xelstrym – dextroamphetamine patch, extended release</emphasis>. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0862f02a-72a8-41cc-8845-57cf4974bb6f</para>
<para id="para-00116">DailyMed. (Updated January 13, 2022). <emphasis effect="italics">Zaleplon, capsule.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=47303145-6788-46bd-b9cc-37b59b145cea</para>
<para id="para-00117">DailyMed. (Updated December 22, 2022). <emphasis effect="italics">Ziprasidone capsule</emphasis>. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8f78b278-a0b3-47ce-bbad-5dad7012896a</para>
<para id="para-00118">DailyMed. (Updated April 14, 2022). <emphasis effect="italics">Zolpidem tartrate tablet</emphasis>, <emphasis effect="italics">film coated.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea2067bd-1622-4d98-8012-2c09405aa88d</para>
<para id="para-00119">DailyMed. (Updated October 10, 2019). <emphasis effect="italics">Zolpidem tartrate</emphasis> <emphasis effect="italics">sublingual tablet.</emphasis> https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44b34e58-114b-4774-9fab-4b188dfe0228</para>
<para id="para-00120">Edinoff, A. N., Raveendran, K., Colon, M. A., Thomas, B. H., Trettin, K. A., Hunt, G. W., Kaye, A. M., Cornett, E. M., &amp; Kaye, A. D. (2022). Selective serotonin reuptake inhibitors and associated bleeding risks: A narrative and clinical review. <emphasis effect="italics">Health Psychology Research,10</emphasis>(4). doi:10.52965/001c.39580</para>
<para id="para-00121">Hedya, S., Avula, A., &amp; Swoboda, H. (2023). <emphasis effect="italics">Lithium toxicity.</emphasis> StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK499992/</para>
<para id="para-00122">Institute for Safe Medication Practices. (2023). <emphasis effect="italics">List of confused drug names.</emphasis> https://www.ismp.org/recommendations/confused-drug-names-list</para>
<para id="para-00123">Lee, S. J., &amp; Green, A. R. (2019). <emphasis effect="italics">Ask the expert: Sedative-hypnotic drugs and related medications</emphasis>. Health in Aging. https://www.healthinaging.org/tools-and-tips/ask-expert-sedative-hypnotic-drugs-and-related-medications</para>
<para id="para-00124">Marazziti, D., Mucci, F., Avella, M., Palagini, L., Simoncini, M., &amp; Dell’Osso, L. (2021). The increasing challenge of the possible impact of ethnicity on psychopharmacology. <emphasis effect="italics">CNS Spectrums, 26</emphasis>(3), 222–231. doi:10.1017/S1092852920000073</para>
<para id="para-00125">National Institute of Mental Health. (2022, September). <emphasis effect="italics">Attention-deficit/hyperactivity disorder.</emphasis> https://www.nimh.nih.gov/health/topics/attention-deficit-hyperactivity-disorder-adhd</para>
<para id="para-00126">National Institute of Mental Health. (2023a, February). <emphasis effect="italics">Bipolar disorder.</emphasis> https://www.nimh.nih.gov/health/topics/bipolar-disorder</para>
<para id="para-00127">National Institute of Mental Health. (2023b, April). <emphasis effect="italics">Depression.</emphasis> https://www.nimh.nih.gov/health/topics/depression</para>
<para id="para-00128">National Institute of Mental Health. (2023c, May). <emphasis effect="italics">Schizophrenia.</emphasis> https://www.nimh.nih.gov/health/topics/schizophrenia</para>
<para id="para-00129">National Institute of Neurological Disorders and Stroke. (n.d.). <emphasis effect="italics">Narcolepsy</emphasis>. https://www.ninds.nih.gov/health-information/disorders/narcolepsy/</para>
<para id="para-00130">Shoar, N. S., Bistas, K., &amp; Saadabadi, A. (2023). <emphasis effect="italics">Flumazenil</emphasis>. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK470180</para>
<para id="para-00131">Van Norman, G. (2023). Off-label use vs off-label marketing of drugs: Part 1: Off-label use—patient harms and prescriber responsibilities. <emphasis effect="italics">JACC: Basic to Translational Science, 8</emphasis>(2), 224–233. https://www.sciencedirect.com/science/article/pii/S2452302X23000116?via%3Dihub</para>
<para id="para-00132">Volkmann, C., Bschor, T., &amp; Köhler, S. (2020). Lithium treatment over the lifespan in bipolar disorders. <emphasis effect="italics">Frontiers in Psychiatry</emphasis>, <emphasis effect="italics">11</emphasis>, 377. https://doi.org/10.3389/fpsyt.2020.00377</para>
</section>
</content>
<glossary>
<definition id="def-00001"><term>cataplexy</term> <meaning>associated with narcolepsy; brief loss of voluntary muscle tone triggered by strong emotion</meaning></definition>
<definition id="def-00002"><term>cognitive-behavioral therapy</term> <meaning>type of psychotherapeutic method that helps people identify maladaptive and negative patterns of thinking that cause a negative influence on behavior and mood; this thinking is challenged and replaced with more desirable, realistic thoughts.</meaning></definition>
<definition id="def-00003"><term>hypnagogic hallucinations</term> <meaning>sleep-related hallucinations that occur as a person is falling asleep; commonly visual and consist of vivid images of patterns, shapes, or people; occasionally may involve sounds or physical sensations.</meaning></definition>
<definition id="def-00004"><term>parasomnia</term> <meaning>any kind of sleep-related disorder that occurs while going to sleep, during the sleep cycle, or when waking up from sleep; symptoms vary but the most common include nightmares, night terrors, sleep paralysis, grinding teeth, sleepwalking, sleep eating, and sleep talking</meaning></definition>
<definition id="def-00005"><term>prodrug</term> <meaning>a drug that is pharmacologically inactive until it is ingested and metabolized into an active form</meaning></definition>
<definition id="def-00006"><term>sleep paralysis</term> <meaning>a temporary inability to move or speak while falling asleep or upon waking</meaning></definition>
</glossary>
</document>